ESR1 and neoplasm: Ecimovic et al. [25] analyzed, in vitro, the ability of sevoflurane to stimulate tumor cell proliferation, migration and invasion in patients with positive (ER+) and negative (ER-) estrogen receptor breast cancer (with the latter not having invasive capacity).